Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADHD Prescriptions Increase 24.5 Percent After Aussie Coverage

This article was originally published in PharmAsia News

Executive Summary

Australian authorities report prescriptions for drugs to treat attention deficit hyperactivity disorder rose by 24.5 percent after the Pharmaceutical Benefits Scheme decided to cover the drugs. Alza's Concerta (methyphenidate hydrochloride), a long-acting stimulate, and Eli Lilly's Strattera (atomoxetine hydrochloride), a non-stimulant, were put on the PBS formulary after the agency decided to cover ADHD beginning last April. The cost of Concerta to patients dropped 80 percent as a result. But the government is about to release the results of a review of the advisability of covering the drugs in the wake of questions raised about the amount of psychiatric drugs prescribed for children. (Click here for more

You may also be interested in...



Novartis Takes Huntington's Path With SMA Therapy Branaplam

With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.

With $850m, Nuvation Aims To Speed Novel Cancer Drugs To Patients

Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.

US FDA Investigators Focusing Inspections On Aseptic Processing Operations

US FDA investigators' increased focus on aseptic operations is resulting in more Form 483 observations of microbiological contamination issues over the past few years.

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel